Tirzepatide is a prescription glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) 30 kg/m (obesity), or 27 kg/m (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, or dyslipidemia)
Only increase if weight loss stalls for 3 or more consecutive weeks, appetite suppression fades before your next injection, or your prescriber recommends escalation based on your individual progress
Constipation is another driver
Mounjaro is licensed for the treatment of type 2 diabetes and for weight management
If youve been riding the compounded peptide wave, nows the time to reassess your strategy and tighten up compliance before the FDA or Big Pharma comes knocking
A bubble occupying 5 units of space means you are injecting 5 fewer units of actual medication
